Atrial fibrillation in the elderly

被引:53
作者
Fang, Margaret C.
Chen, Jane
Rich, Michael W.
机构
[1] Univ Calif San Francisco, Hosp Grp, Div Gen Internal Med, San Francisco, CA 94143 USA
[2] Washington Univ, Sch Med, Div Cardiovasc, St Louis, MO 63110 USA
关键词
anti-arrhythmic; anticoagulants; atrial fibrillation; elderly; hemorrhage; rate control; rhythm control; stroke; CLINICAL CLASSIFICATION SCHEMES; MAJOR BLEEDING COMPLICATIONS; ORAL ANTICOAGULANT-THERAPY; LONG-TERM WARFARIN; QUALITY-OF-LIFE; RISK-FACTORS; RADIOFREQUENCY ABLATION; NATIONAL REGISTRY; HEMORRHAGIC COMPLICATIONS; INTRACRANIAL HEMORRHAGE;
D O I
10.1016/j.amjmed.2007.01.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation is increasingly prevalent among older adults. It causes approximately 24% of strokes in patients aged 80 to 89 years. The management of atrial fibrillation is directed at preventing thromboembolism and controlling the heart rate and rhythm. Stroke prevention is most effectively accomplished through administering anticoagulants such as warfarin, although older patients have higher hemorrhagic risk. Cognitive dysfunction, functional impairments, and increased fall risk further complicate warfarin management in elderly patients. The use of risk stratification schemes can help guide the anticoagulation decision, although the benefits of warfarin generally outweigh the risks in most older patients with atrial fibrillation. Pharmacologic rate control has been shown to result in similar outcomes compared with pharmacologic restoration of sinus rhythm and should be the initial therapy for elderly patients. Antiarrhythmic medications should be selected based on an individual patient's coexisting medical conditions. In symptomatic patients who fail pharmacologic therapy, invasive strategies such as AV nodal ablation may help improve quality of life and symptoms, although such strategies do not obviate the need for antithrombotic therapy. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:481 / 487
页数:7
相关论文
共 73 条
[1]  
Ad N, 2000, Semin Thorac Cardiovasc Surg, V12, P56
[2]  
Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[3]  
Albers GW, 2003, LANCET, V362, P1691
[4]  
American Geriatrics Society Clinical Practice Committee, 2002, J Am Geriatr Soc, V50, P1439
[5]  
Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273
[6]   Determinants of compliance with anticoagulation: A case-control study [J].
Arnsten, JH ;
Gelfand, JM ;
Singer, DE .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (01) :11-17
[7]   Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin [J].
Beyth, RJ ;
Quinn, LM ;
Landefeld, CS .
AMERICAN JOURNAL OF MEDICINE, 1998, 105 (02) :91-99
[8]   A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial [J].
Beyth, RJ ;
Quinn, L ;
Landefeld, CS .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) :687-695
[9]   Why do patients with atrial fibrillation not receive warfarin? [J].
Bungard, TJ ;
Ghali, WA ;
Teo, KK ;
McAlister, FA ;
Tsuyuki, RT .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :41-46
[10]   Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function [J].
Chen, MS ;
Marrouche, NF ;
Khaykin, Y ;
Gillinov, AM ;
Wazni, O ;
Martin, DO ;
Rossillo, A ;
Verma, A ;
Cummings, J ;
Erciyes, D ;
Saad, E ;
Bhargava, M ;
Bash, D ;
Schweikert, R ;
Burkhardt, D ;
Williams-Andrews, M ;
Perez-Lugones, A ;
Abdul-Karim, A ;
Saliba, W ;
Natale, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) :1004-1009